Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
about
Sunitinib in solid tumorsDermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: report of a case and literature review of kinase inhibitors and blocking antibodiesMetabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma.Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management.Pazopanib: therapeutic developments.Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.Targeted therapies for renal cell carcinoma: review of adverse event management strategies.Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells.Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female.[Cutaneous side effects of targeted cancer drugs].
P2860
Q28245467-33A3DA55-0FA5-40C0-91ED-EFF1D5A376BFQ33885559-18F7B8C6-25B5-4FF5-A588-2EE9619C98C3Q33916002-22B9EE3A-73EA-4A02-BA5D-2B6F0E980396Q34591507-19083D4E-9477-4514-8CD3-AA201EC94675Q35023711-B7F02DAA-0096-4729-828C-B706889E72D5Q37258222-772063A6-C4FB-4AFD-A180-0EE58EF3F002Q37508022-A1E8F8A0-7800-41DF-B562-F85AF8BE0ABFQ37629866-78240002-0AEC-4B6B-A2AB-7B60DC6CF4CEQ37642770-303A858F-BCD7-4224-A3D3-684C1E47F603Q37930711-E3C56AE1-A25E-4772-916E-ABE08CAD12BAQ37974894-A6F2D602-D955-4DD9-9DC7-06BA0744B5C7Q37983527-A65B4C2C-A2E3-4CBB-84D4-E23F92581E8DQ38948950-56EFC672-7B99-4693-9C33-3C5E63FD2F61Q39048761-2A3C8766-90C3-496F-A15C-22B72D06B415Q39379568-8AB547B2-B61F-496C-9CD7-477997095EA7Q39396441-325B8EEA-8089-41DA-937F-698F2584AE92Q43035310-D1F89398-C16D-46C5-8783-AB09CFAE86ECQ47350013-63B7FC6A-491A-458C-96B6-FC227B9E0C77Q49766022-858A8384-9B40-4966-A5B3-BDFB3976F372Q53193539-DA7FB54C-DAB0-4D9E-87C3-C2C7AECEE00E
P2860
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@ast
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@en
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@nl
type
label
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@ast
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@en
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@nl
prefLabel
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@ast
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@en
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
@nl
P2093
P1476
Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
@en
P2093
P2860
P2888
P304
P356
10.1007/S00520-008-0409-1
P577
2008-02-15T00:00:00Z